We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Verona Pharma Plc | LSE:VRP | London | Ordinary Share | GB00BYW2KH80 | ORD 5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 55.00 | 45.00 | 65.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
Hot Features
Premium
TIDMVRP
LONDON, April 04, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP)
(Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical
company focused on developing and commercializing innovative therapies
for respiratory diseases, announces that, on April 1, 2019 (the "Grant
Date"), it granted the following options over ordinary shares of GBP0.05
each (the "Ordinary Shares") and American Depositary Shares ("ADS") and
restricted share units ("RSUs") and Restricted American Depositary Share
Units ("RADSUs") to directors and employees of Verona Pharma under and
in accordance with Verona Pharma's 2017 Incentive Award Plan (which is
set out in Verona Pharma's 2018 annual report and 20-F):
-- 2,592,322 options to purchase Ordinary Shares;
-- 163,841 options to purchase ADSs, representing 1,310,728 Ordinary Shares;
-- 523,392 RSUs; and
-- 27,138 RADSUs, representing 217,104 Ordinary Shares.
Each RSU and RADSU represents an unfunded, unsecured right to receive,
on the applicable settlement date, one Ordinary Share or the equivalent
number of ADSs, as applicable, or an amount in cash or other
consideration. Except where the context indicates otherwise, references
hereunder to the Ordinary Shares shall be deemed to include a number of
ADSs equal to an Ordinary Share. No consideration was paid in respect
of the grant of awards.
PDMR Dealings
Verona Pharma notifies the following transactions by persons discharging
managerial responsibilities ("PDMRs") in its Ordinary Shares through the
grant of options over Ordinary Shares and ADSs and RSUs under and in
accordance with Verona Pharma's 2017 Incentive Award Plan.
Name Options over RSUs and RADSUs
---------- --------------------------------------- ----------------------------
Dr. 1,026,944 Ordinary Shares 266,424 RSUs
Jan-Anders
Karlsson,
CEO
---------- --------------------------------------- ----------------------------
Piers 359,430 Ordinary Shares 93,247 RSUs
Morgan,
CFO
---------- --------------------------------------- ----------------------------
Dr. 70,000 ADSs 15,000 RADSUs
Kathleen (representing 560,000 Ordinary Shares) (representing 120,000 RSUs)
Rickard,
CMO
---------- --------------------------------------- ----------------------------
Claire 256,735 Ordinary Shares 66,603 RSUs
Poll,
Legal
Counsel
---------- --------------------------------------- ----------------------------
The options over Ordinary Shares have an exercise price of GBP0.58 per
Ordinary Share, being the closing mid-market price on March 29, 2019.
The options over ADSs have an exercise prce of GBP4.64 per ADS, on the
basis that each ADS represents 8 ordinary shares. The RSUs also have a
value of GBP0.58 per RSU and the RADSUs have a value of GBP4.64 per
RADSU.
The options, RSUs and RADSUs set forth in the table above will vest as
to 50% of the Ordinary Shares or ADSs (as appropriate) in three
substantially equal annual instalments following the Grant Date and as
to 50% of the Ordinary Shares or ADSs (as appropriate) in four
substantially equal annual instalments following the Grant Date.
The notification of dealing form in respect of option/RSU awards for
each PDMR can be found below.
For further information, please contact:
Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer info@veronapharma.com
Victoria Stewart, Director of Communications
Stifel Nicolaus Europe Limited (Nominated Adviser Tel: +44 (0) 20 7710 7600
and UK Broker)
Stewart Wallace / Jonathan Senior / Ben Maddison SNELVeronaPharma@stifel.com
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Dr. Jan-Anders Karlsson
Reason for the
2 notification
a) Position/status Chief Executive Officer
Initial
notification
b) /Amendment Initial Notification
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
a) Name Verona Pharma plc
Legal Entity
b) Identifier 213800EVI6O6J3TIAL06
Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
4 where transactions have been conducted
Description of
the financial
instrument, type
a) of instrument Ordinary shares of 5p each
Identification
code ISIN Code: GB00BYW2KH80
Nature of the
b) transaction Issue of options over Ordinary Shares
Price(s) and
c) volume(s)
Price(s) Volume(s)
Exercise Price: GBP0.58 1,026,944 Options over Ordinary Shares
--- ---------------- ----------------------------------------------------------- --------------------------------------
Aggregated
d) information N/a (single transaction)
- Aggregated
volume
- Price
Date of the
e) transaction 1 April 2019
Place of the
f) transaction London Stock Exchange, AIM
Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
4 where transactions have been conducted
Description of
the financial
instrument, type
a) of instrument Ordinary shares of 5p each
Identification
code ISIN Code: GB00BYW2KH80
Grant of RSUs, each of which represents an unfunded,
unsecured right to receive, on the applicable settlement
Nature of date, one Ordinary Share or an amount in cash or other
b) transaction consideration
Price(s) and
c) volume(s)
Price(s) Volume(s)
No consideration 266,424
-------------------------------------------------------------------------------- --------------------------------------
Aggregated
d) information N/a (single transaction)
- Aggregated
volume
- Price
Date of the
e) transaction 1 April 2019
Place of the
f) transaction London Stock Exchange, AIM
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Piers Morgan
Reason for the
2 notification
a) Position/status Chief Financial Officer
Initial
notification
b) /Amendment Initial Notification
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
a) Name Verona Pharma plc
Legal Entity
b) Identifier 213800EVI6O6J3TIAL06
Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
4 where transactions have been conducted
Description of
the financial
instrument, type
a) of instrument Ordinary shares of 5p each
Identification
code ISIN Code: GB00BYW2KH80
Nature of the
b) transaction Issue of options over Ordinary Shares
Price(s) and
c) volume(s)
Price(s) Volume(s)
Exercise Price: GBP0.58 Options over 359,430 Ordinary Shares
Aggregated
d) information N/a (single transaction)
- Aggregated
volume
- Price
Date of the
e) transaction 1 April 2019
Place of the
f) transaction London Stock Exchange, AIM
Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
4 where transactions have been conducted
Description of
the financial
instrument, type
a) of instrument Ordinary shares of 5p each
Identification
code ISIN Code: GB00BYW2KH80
Grant of RSUs, each of which represents an unfunded,
unsecured right to receive, on the applicable settlement
Nature of date, one Ordinary Share or an amount in cash or other
b) transaction consideration
Price(s) and
c) volume(s)
Price(s) Volume(s)
No consideration 93,247
-------------------------------------------------------------------------------- --------------------------------------
Aggregated
d) information N/a (single transaction)
- Aggregated
volume
- Price
Date of the
e) transaction 1 April 2019
Place of the
f) transaction London Stock Exchange, AIM
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Dr. Kathleen Rickard
Reason for the
2 notification
a) Position/status Chief Medical Officer
Initial
notification
b) /Amendment Initial Notification
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
a) Name Verona Pharma plc
Legal Entity
b) Identifier 213800EVI6O6J3TIAL06
Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
4 where transactions have been conducted
Description of American Depositary Shares ("ADSs"), representing
the financial ordinary shares of 5p each, on deposit with a U.S.
instrument, type banking institution selected by the Company and which
a) of instrument are registered pursuant to a Form F-6.
Identification
code ISIN Code: GB00BYW2KH80
Nature of the
b) transaction Issue of options over ADSs
Price(s) and
c) volume(s)
Price(s) Volume(s)
Exercise Price: GBP4.64 Options over 70,000 ADSs
(representing 560,000 Ordinary Shares)
--- ---------------- ----------------------------------------------------------- --------------------------------------
Aggregated
d) information N/a (single transaction)
- Aggregated
volume
- Price
Date of the
e) transaction 1 April 2019
Place of the
f) transaction NASDAQ
Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
4 where transactions have been conducted
Description of
the financial
instrument, type
a) of instrument ADSs
Identification
code ISIN Code: US9250501064
Grant of RADSUs, each of which represents an unfunded,
Nature of unsecured right to receive, on the applicable settlement
b) transaction date, one ADS or an amount in cash or other consideration
Price(s) and
c) volume(s)
Price(s) Volume(s)
No consideration 15,000
(representing 120,000 Ordinary Shares)
-------------------------------------------------------------------------------- --------------------------------------
d) Aggregated N/a (single transaction)
information
- Aggregated volume
- Price
e) Date of the 1 April 2019
transaction
f) Place of the NASDAQ
transaction
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Claire Poll
2 Reason for the notification
a) Position/status Legal Counsel
b) Initial Initial Notification
notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Verona Pharma plc
b) Legal Entity 213800EVI6O6J3TIAL06
Identifier
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
a) Description of Ordinary shares of 5p each
the financial
instrument,
type of
instrument
Identification ISIN Code: GB00BYW2KH80
code
b) Nature of the Issue of options over Ordinary Shares
transaction
c) Price(s) and volume(s)
Price(s) Volume(s)
Exercise Price: GBP0.58 Options over 256,735 Ordinary Shares
d) Aggregated N/a (single transaction)
information
- Aggregated volume
- Price
e) Date of the 1 April 2019
transaction
f) Place of the London Stock Exchange, AIM
transaction
Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
4 where transactions have been conducted
Description of
the financial
instrument,
type of
a) instrument Ordinary shares of 5p each
Identification
code ISIN Code: GB00BYW2KH80
Grant of RSUs, each of which represents an unfunded,
unsecured right to receive, on the applicable settlement
Nature of date, one Ordinary Share or an amount in cash or other
b) transaction consideration
Price(s) and
c) volume(s)
Price(s) Volume(s)
No consideration 66,603
------------------------------------------------------------------------------ ---------
d) Aggregated N/a (single transaction)
information
- Aggregated volume
- Price
e) Date of the 1 April 2019
transaction
f) Place of the London Stock Exchange, AIM
transaction
(END) Dow Jones Newswires
April 04, 2019 02:00 ET (06:00 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Verona Pharma Chart |
1 Month Verona Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
